Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ALDX

Aldeyra Therapeutics Inc

Dec 13 • 04:00PM ET

4.90

Dollar change -0.11
Percentage change -2.20	%

Healthcare • Biotechnology • USA • NASD

Peers: NBIX IONS XOMA PRTA CRBP ITCI BHVN AUPH ACAD RIGL

| Held by: VTI IWM VXF DWAS IWN VTWO VHT IWC DFAS ITOT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.75	Insider Own	2.90%	Shs Outstand	59.55M	Perf Week	-6.13%
Market Cap	285.38M	Forward P/E	-	EPS next Y	-0.06	Insider Trans	-1.48%	Shs Float	57.82M	Perf Month	11.11%
Income	-44.80M	PEG	-	EPS next Q	-0.24	Inst Own	61.58%	Short Float	5.90%	Perf Quarter	-17.09%
Sales	0.00M	P/S	-	EPS this Y	-41.61%	Inst Trans	5.58%	Short Ratio	7.18	Perf Half Y	31.37%
Book/sh	1.43	P/B	3.43	EPS next Y	93.06%	ROA	-33.86%	Short Interest	3.41M	Perf Year	59.09%
Cash/sh	1.25	P/C	3.92	EPS next 5Y	-	ROE	-43.05%	52W Range	2.71 - 6.55	Perf YTD	39.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.70%	ROI	-44.72%	52W High	-25.16%	Beta	1.37
Dividend TTM	-	Quick Ratio	6.64	Sales past 5Y	0.00%	Gross Margin	-	52W Low	80.81%	ATR (14)	0.31
Dividend Ex-Date	-	Current Ratio	6.64	EPS Y/Y TTM	3.07%	Oper. Margin	-	RSI (14)	46.28	Volatility	6.43% 6.50%
Employees	10	Debt/Eq	0.18	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	10.29
Option/Short	Yes / Yes	LT Debt/Eq	0.18	EPS Q/Q	-82.93%	Payout	-	Rel Volume	0.64	Prev Close	5.01
Sales Surprise	-	EPS Surprise	-1.42%	Sales Q/Q	-	Earnings	Nov 07	Avg Volume	475.13K	Price	4.90
SMA20	-0.38%	SMA50	-5.05%	SMA200	10.11%	Trades		Volume	303,095	Change	-2.20%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-03-24	Upgrade	Oppenheimer	Perform → Outperform	$10
Apr-02-24	Resumed	H.C. Wainwright	Buy	$10
Apr-27-22	Resumed	H.C. Wainwright	Buy	$15
Feb-08-21	Initiated	H.C. Wainwright	Buy	$26
Dec-16-20	Initiated	Berenberg	Buy	$32
Oct-30-20	Initiated	Jefferies	Buy	$24
Oct-16-20	Initiated	BTIG Research	Buy	$29
Sep-22-20	Initiated	Alliance Global Partners	Buy	$32
May-12-20	Initiated	Oppenheimer	Outperform	$12
Dec-04-18	Initiated	Citigroup	Buy	$23
Sep-26-18	Reiterated	Cantor Fitzgerald	Overweight	$23 → $30
Sep-13-18	Initiated	Janney	Buy
Jan-26-18	Initiated	Seaport Global Securities	Buy	$13
Sep-26-16	Initiated	H.C. Wainwright	Buy	$18
Jul-01-16	Initiated	Stifel	Buy	$16
Jul-01-15	Initiated	Canaccord Genuity	Buy	$16
Mar-25-15	Initiated	Chardan Capital Markets	Buy	$16
Mar-20-15	Reiterated	H.C. Wainwright	Buy	$13 → $14
Nov-18-14	Initiated	H.C. Wainwright	Buy	$13
Jun-19-14	Initiated	Aegis Capital	Buy	$35

Show Previous Ratings

Dec-09-24 10:05AM	Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock? (Zacks)
Dec-02-24 07:00AM	Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference (Business Wire)
Nov-18-24 07:00AM	Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement (Business Wire) +11.64%
Nov-14-24 07:00AM	Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference (Business Wire)
Oct-31-24 07:00AM	Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting (Business Wire)
07:00AM	Loading…
Oct-03-24 07:00AM	Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease (Business Wire)
Sep-05-24 07:00AM	Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-30-24 10:38AM	Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory (Insider Monkey) +7.07%
Aug-09-24 06:32AM	Aldeyras Phase III clinical trial of Reproxalap meets primary endpoint (Clinical Trials Arena) +21.72%
Aug-08-24 07:00AM	Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap (Business Wire) +28.53%
Aug-07-24 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap (Business Wire) -5.23%
Jun-20-24 07:00AM	Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable (Business Wire) -6.47%
Jun-14-24 06:32AM	Aldeyra Therapeutics concludes subject enrolment in dry eye disease trial (Clinical Trials Arena)
Jun-13-24 07:00AM	Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease (Business Wire)
Jun-12-24 07:00AM	Aldeyra Therapeutics to Host Investor Roundtable Q&A (Business Wire)
07:00AM	Loading…
May-29-24 07:00AM	Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-14-24 09:40AM	Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year? (Zacks) +12.70%
May-08-24 03:12PM	Aldeyra Therapeutics Enrolls First Patient in Phase 3 Dry Eye Chamber Study (MT Newswires)
07:00AM	Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease (Business Wire)
May-03-24 08:52AM	ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024 (InvestorPlace)
Apr-25-24 07:00AM	Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day (Business Wire)
Apr-22-24 09:40AM	Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-18-24 07:00AM	Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024 (Business Wire)
Apr-06-24 06:37AM	Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why (Zacks)
Apr-04-24 12:36PM	Health Care Roundup: Market Talk (The Wall Street Journal) +12.89%
Apr-03-24 02:58PM	Aldeyra's Dry Eye Disease Drug May Be on Path for FDA Approval (Barrons.com) +16.90%
Mar-28-24 07:00AM	Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease (Business Wire) +6.17%
Mar-27-24 01:21PM	Notice to Long-Term Aldeyra Therapeutics, Inc. (ALDX) Investors (Newsfile) +5.48%
Mar-13-24 02:33AM	Aldeyra Therapeutics Inc President and CEO Todd Brady Sells Company Shares (GuruFocus.com)
Mar-06-24 09:40AM	Here's Why You Should Invest in Aldeyra (ALDX) Stock Now (Zacks)
07:00AM	Loading…
Feb-06-24 07:00AM	Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (Business Wire) +7.05%
Jan-04-24 07:00AM	Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases (Business Wire)
Dec-19-23 07:27AM	UPDATE 1-Aldeyra Therapeutics' skin disease drug succeeds in mid-stage study (Reuters) +18.58%
07:05AM	Aldeyra Therapeutics' eczema drug succeeds in mid-stage study (Reuters)
07:00AM	Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX629 in Patients with Atopic Dermatitis (Business Wire)
Dec-18-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis (Business Wire)
Dec-06-23 11:55AM	13 Hot Penny Stocks To Buy According to Hedge Funds (Insider Monkey)
Dec-05-23 09:00AM	Should You Buy Aldeyra Therapeutics (ALDX) Ahead of Earnings? (Zacks)
Nov-27-23 04:07PM	Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease (Business Wire)
Nov-01-23 10:34AM	Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today? (InvestorPlace) +48.54%
07:05AM	Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap (Business Wire)
Oct-18-23 08:30AM	Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More (Zacks) -5.98%
Oct-17-23 10:13AM	Aldeyra (ALDX) Plummets on Dry Eye Disease Drug's Setback (Zacks)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Jul-20-23 09:55AM	Can Aldeyra Therapeutics, Inc. (ALDX) Climb 107.66% to Reach the Level Wall Street Analysts Expect? (Zacks)
Jul-06-23 07:00AM	Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum (Business Wire)
Jun-29-23 07:00AM	Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX2191 in Patients with Retinitis Pigmentosa (Business Wire)
05:20AM	The Petri Dish: Startup behind VR treatments gets $16M, Aldeyra notches midstage trial win (American City Business Journals)
Jun-28-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa (Business Wire)
Jun-27-23 12:03PM	Aldeyra Therapeutics' Chronic Cough Potential Shows Significant Reduction In Cough Frequency Versus Placebo (Benzinga)
07:00AM	Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX629 in Patients With Chronic Cough (Business Wire)
Jun-26-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX629 in Patients with Chronic Cough (Business Wire) +5.63%
Jun-23-23 07:00AM	Aldeyra Therapeutics to Join the Russell 2000® and Russell 3000® Indexes (Business Wire) -8.26%
Jun-21-23 09:34AM	Aldeyra Therapeutics Provides Regulatory Update on ADX-2191 (Business Wire) -27.44%
Jun-16-23 10:26AM	Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study (Zacks)
Jun-15-23 02:52PM	Why Aldeyra Therapeutics Stock Is Trading Higher Today (Benzinga)
07:08AM	Aldeyra Therapeutics eye treatment meets late-stage study main goal (Reuters)
07:00AM	Aldeyra Therapeutics Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE2 Trial of Reproxalap in Allergic Conjunctivitis (Business Wire)
Jun-14-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE2 Trial in Allergic Conjunctivitis (Business Wire)
Jun-02-23 07:00AM	Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference (Business Wire)
May-07-23 07:30AM	This Biotech Is a Sight for Sore Eyes (TheStreet.com)
May-04-23 07:00AM	Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights (Business Wire)
Apr-13-23 07:00AM	Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis (Business Wire)
Apr-06-23 07:00AM	Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis (Business Wire)
Mar-30-23 07:00AM	Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough (Business Wire)
Mar-16-23 07:00AM	Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX2191 in Retinitis Pigmentosa (Business Wire)
Mar-11-23 02:59AM	Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-09-23 11:05PM	Q4 2022 Aldeyra Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +7.19% -9.11%
07:00AM	Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights (Business Wire)
Mar-02-23 07:00AM	FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma (Business Wire) +5.78%
Mar-01-23 07:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2022 Financial Results and Discuss Recent Corporate Highlights (Business Wire)
Feb-28-23 03:22PM	Aldeyra Highlights 12-Month Safety Data Of Reproxalap In Dry Eye Disease Patients (Benzinga) -5.06%
07:00AM	Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease (Business Wire)
Feb-23-23 07:00AM	Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy (Business Wire) +5.91%
Feb-22-23 05:26AM	Owning 40% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), (Simply Wall St.)
Feb-16-23 07:00AM	Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX629 Into New Phase 2 Systemic Disease Trials (Business Wire) +5.46%
Feb-09-23 07:00AM	Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference (Business Wire)
Feb-07-23 07:00AM	Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease (Business Wire) +9.37%
Jan-12-23 06:37AM	Insiders made the right call by buying US$1.2m Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) stock this year, currently sit on US$349k profit (Simply Wall St.) +7.29%
Dec-21-22 07:00AM	Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX2191 for the Treatment of Primary Vitreoretinal Lymphoma (Business Wire) +6.23%
Dec-13-22 01:37PM	Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol Intoxication (Benzinga)
08:00AM	Aldeyra Therapeutics Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial (Business Wire)
Dec-01-22 08:00AM	Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA (Business Wire) +10.00%
Nov-29-22 08:00AM	Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease (Business Wire) +5.00%
Nov-10-22 07:00AM	Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights (Business Wire) +6.18%
Nov-03-22 08:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights (Business Wire)
Nov-02-22 01:45PM	Aldeyra Therapeutics Is a Speculative Stock Worth a Small Position (TheStreet.com)
Oct-26-22 08:00AM	Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting (Business Wire) +7.81%
Oct-06-22 12:23PM	Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision Disorder (Benzinga)
07:00AM	Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy (Business Wire)
Oct-05-22 04:05PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy (Business Wire)
Sep-14-22 08:00AM	Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones (Business Wire)
Sep-07-22 08:00AM	Aldeyra Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Sep-01-22 06:56AM	Owning 48% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), (Simply Wall St.)
Aug-15-22 09:55AM	Aldeyra Therapeutics, Inc. (ALDX) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Aug-07-22 03:00AM	Aldeyra Therapeutics (ALDX) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-05-22 07:00AM	Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights (Business Wire) +10.90%
06:09AM	Joseph Edelman Just Bought 2.2% More Shares In Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Simply Wall St.)
Aug-01-22 02:55PM	Oppenheimer Says S&P 500 Could Rise Another 12% by Year-End and These Stocks Could Follow (TipRanks)
Jul-29-22 08:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights (Business Wire)

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Machatha Stephen	Chief Development Officer	Aug 12 '24	Sale	4.74	16,041	75,975	236,771	Aug 14 04:24 PM
Greenberg Bruce	See Remarks	Aug 12 '24	Sale	4.74	10,834	51,313	126,382	Aug 14 04:24 PM
Greenberg Bruce	Officer	Aug 12 '24	Proposed Sale	5.10	10,834	55,253		Aug 12 06:07 PM
Machatha Stephen	Officer	Aug 12 '24	Proposed Sale	5.10	16,041	81,809		Aug 12 05:45 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 04 '24	Buy	4.67	140,281	655,112	9,238,139	Apr 08 05:32 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 05 '24	Buy	4.74	37,712	178,755	9,275,851	Apr 08 05:32 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 03 '24	Buy	4.09	309,847	1,267,274	9,097,858	Apr 03 05:22 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 02 '24	Buy	3.44	186,051	640,015	8,788,011	Apr 03 05:22 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 01 '24	Buy	3.25	8,374	27,216	8,601,960	Apr 03 05:22 PM
Greenberg Bruce	See Remarks	Mar 11 '24	Sale	3.41	13,201	44,968	120,699	Mar 12 08:07 PM
Machatha Stephen	Chief Development Officer	Mar 11 '24	Sale	3.41	18,231	62,102	255,032	Mar 12 08:04 PM
Machatha Stephen	Chief Development Officer	Mar 12 '24	Sale	3.16	11,537	36,503	243,495	Mar 12 08:04 PM
Brady Todd C	President and CEO	Mar 11 '24	Sale	3.27	97,914	320,521	1,556,622	Mar 12 08:01 PM
Brady Todd C	President and CEO	Mar 12 '24	Sale	3.05	85,324	260,238	1,471,298	Mar 12 08:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALDX

Aldeyra Therapeutics Inc

Upgrade your FINVIZ experience